EGFR and neoplasm: Nevertheless, we obtained samples from the same primary tumor site from 3 treatment time points from a patient (TH226) whose tumor contained a standard EGFR exon 19 deletion oncogenic mutation and was treated with the EGFR inhibitor osimertinib (Figures S5A–S5C).